Empagliflozin 25 mg for Epilepsy

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
EpilepsyEmpagliflozin 25 mg - Drug
Eligibility
18 - 45
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether a diabetes drug can be used to treat epilepsy in adults who haven't responded to other drugs.

Treatment Effectiveness

Study Objectives

3 Primary · 1 Secondary · Reporting Duration: 2 weeks

2 weeks
Body Weight Changes
Change in blood glucose while on empagliflozin
Seizures
Number of participants with adverse effects from empagliflozin

Trial Safety

Trial Design

2 Treatment Groups

Empagliflozin / Placebo
1 of 2
Placebo / Empagliflozin
1 of 2

Experimental Treatment

18 Total Participants · 2 Treatment Groups

Primary Treatment: Empagliflozin 25 mg · Has Placebo Group · Phase < 1

Empagliflozin / PlaceboExperimental Group · 2 Interventions: Empagliflozin 25 mg, Placebo · Intervention Types: Drug, Drug
Placebo / EmpagliflozinExperimental Group · 2 Interventions: Empagliflozin 25 mg, Placebo · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Empagliflozin 25 mg
2019
Completed Phase 2
~60
Placebo
1995
Completed Phase 3
~2670

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 2 weeks

Who is running the clinical trial?

Washington University School of MedicineLead Sponsor
1,805 Previous Clinical Trials
2,278,597 Total Patients Enrolled
1 Trials studying Epilepsy
90 Patients Enrolled for Epilepsy
Kwee L ThioPrincipal InvestigatorWashington University School of Medicine

Eligibility Criteria

Age 18 - 45 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have focal, generalized, or combined generalized and focal epilepsy.
References